ONO-4538
ONO-4538 is a pharmaceutical drug with 20 clinical trials. Currently 10 active trials ongoing. Historical success rate of 90.0%.
Success Metrics
Based on 9 completed trials
Phase Distribution
Phase Distribution
11
Early Stage
6
Mid Stage
3
Late Stage
Highest Phase Reached
Phase 3Trial Status & Enrollment
90.0%
9 of 10 finished
10.0%
1 ended early
10
trials recruiting
20
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Study to ONO-4538 in Patients With Rhabdoid Tumor
ONO-4538 Study in Patients With Richter's Transformation
Study of ONO-4578 With and Without ONO-4538 in Subjects Advanced or Metastatic Solid Tumors
Study of ONO-7914 Alone and in Combination With ONO-4538 in Patients With Solid Tumors
ONO-4538 Phase II Rollover Study (ONO-4538-98)
Clinical Trials (20)
Study to ONO-4538 in Patients With Rhabdoid Tumor
ONO-4538 Study in Patients With Richter's Transformation
Study of ONO-4578 With and Without ONO-4538 in Subjects Advanced or Metastatic Solid Tumors
Study of ONO-7914 Alone and in Combination With ONO-4538 in Patients With Solid Tumors
ONO-4538 Phase II Rollover Study (ONO-4538-98)
A PhaseⅠStudy of ONO-7475 in Combination With ONO-4538 and Gemcitabine Plus Nab-paclitaxel (GnP), the Standard of Care, and ONO-7475 in Combination With GnP in Patients With Pancreatic Cancer
ONO-4538 Study in Patients With Advanced Non-Small Cell Lung Cancer
An Open-label, Uncontrolled Study of ONO-4578 and ONO-4538 in Combination With Standard-of-care Modified FOLFIRINOX (mFFX) or Gemcitabine Plus Nab-paclitaxel (GnP) Therapy as First-line Treatment in Patients With Metastatic Pancreatic Cancer
ONO-4538 Study in Patients With Advanced Non-Small Cell Lung Cancer
An Open-label, Uncontrolled Study of ONO-7913 and ONO-4538 in Combination With Modified FOLFIRINOX Therapy, the Standard of Care, as First-line Treatment in Patients With Metastatic Pancreatic Cancer
The Study of ONO-7913, ONO-4538 and the Standard of Care as First-line Treatment in Patients Colorectal Cancer
A Study to Evaluate the Efficacy and Safety of ONO-4538 in Combination With Ipilimumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)
Study of ONO-4578 and XELOX/FOLFOX Plus Bevacizumab in Colorectal Cancer
An Open-label, Uncontrolled Study of ONO-4578 and ONO-4538 in Combination With Standard-of-care Docetaxel and Ramucirumab as Second-line Therapy in Patients With Advanced or Recurrent Non-small Cell Lung Cancer
ONO-4538 Phase I Study in Patients With Solid Tumor
Study of ONO-4538 in Non-Squamous Non-Small Cell Lung Cancer (TASUKI-52)
Study of ONO-4538 in Unresectable Advanced or Recurrent Gastric Cancer
Study of ONO-4538 in Gastric Cancer
ONO-4538 Phase I Study in Patients With Solid Tumor
ONO-4538 Phase I Study in Patients With Advanced Malignant Solid Tumors in Japan
All 20 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 20